Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $206,850.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the sale, the insider owned 26,250 shares of the company’s stock, valued at approximately $723,975. This represents a 22.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total transaction of $210,150.00.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $26.72 on Thursday. Maze Therapeutics, Inc. has a 52 week low of $14.16 and a 52 week high of $53.65. The company’s 50 day moving average price is $28.76 and its two-hundred day moving average price is $31.34. The stock has a market cap of $1.48 billion, a P/E ratio of -10.60 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, equities analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and an average target price of $66.00.

Institutional Trading of Maze Therapeutics

A number of institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Maze Therapeutics in the 1st quarter worth approximately $57,000. Goldman Sachs Group Inc. bought a new stake in Maze Therapeutics during the 1st quarter valued at $145,000. Rhumbline Advisers purchased a new stake in shares of Maze Therapeutics during the first quarter worth $80,000. Geode Capital Management LLC boosted its holdings in shares of Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after acquiring an additional 18,773 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.